Toronto-based panCELLa and CCRM have executed a collaboration agreement using novel technology to generate commercial-use and clinical-grade iPSC lines which will be made available to academia and industry to enable the development of new therapies.   “panCELLa is an innovative company and a key partner in our local ecosystem. We’re pleased to support their efforts to develop novel engineered cell lines that will enable multiple indications representing significant unmet needs,” said Michael May...